Au NP Honeycomb-Patterned Films with Controllable Pore Size and Their Surface-Enhanced Raman Scattering

Honeycomb-patterned films (HPFs) of Au nanoparticles (Au NPs) with pore size controlled by varying the quantity of Au NPs or using modified agents of different mercaptans (C₁₄H₂₉SH, C₁₆H₃₃SH, and C₁₈H₃₇SH) were prepared. The strength of the HPFs containing Au NPs can be enhanced because of the addition of polymers including polystyrene, poly­(l-lactic acid), and poly­(methyl methacrylate-<i>co</i>-ethyl acrylate). With an increase in the amount of polymer and the number of Au NPs or the chain length of the modified agents, the pore size of HPFs decreases, indicating that the pore size can be well controlled by adjusting the above factors. Interestingly, HPFs with elliptical pores that were created by the direction of the air flow were observed. The pore diameter on the outer rim is smaller than that in the center, which should be because of the subordinate evaporation of the solvent in the center. Sponge structures were observed in the cross sections of the walls of HPFs, which should be produced by microphase separation. The HPFs consisting of Au NPs with controllable pore size exhibited stronger surface-enhanced Raman scattering. We believe that the HPFs composed of metal NPs such as Au, Ag, and Cu are exploited in multispectral scanners, nanophotons, and sensors

Regions of increased grey matter volume from baseline to follow-up in patients with schizophrenia.

<p>Regions of increased grey matter volume from baseline to follow-up in patients with schizophrenia.</p

Regions of decreased grey matter volume at baseline in antipsychotic-naïve patients with schizophrenia compared to healthy controls. <i>P</i><0.001, uncorrected, threshold = 50.

<p>Regions of decreased grey matter volume at baseline in antipsychotic-naïve patients with schizophrenia compared to healthy controls. <i>P</i><0.001, uncorrected, threshold = 50.</p

Distribution of complications among the cases in the two groups.

1<p>Platelet <100×10⁹/L;</p>2<p>Hemoglobin <120 g/L;</p>3<p>Total bilirubin >43 µmol/L;</p>4<p>Plasma glucose <2.8 mmol/L;</p>5<p>Plasma potassium <3.5 mmol/L.</p

Laboratory indices of cases among chemoprophylaxis group, uncomplicated group, and complications group (mean±SD).

*<p>Significant differences were observed between any two groups.</p>#<p>Significant differences were observed between the chemoprophylaxis group and complications group or between the uncomplicated group and complications group.</p><p>̂Significant differences were observed between chemoprophylaxis group and uncomplicated group or between the chemoprophylaxis group and complications group.</p

Temporal distribution of prevalence of <i>Plasmodium falciparum</i> malaria based on the U.N. populations at the UNMIS level 2 hospital in Wau, July 2006–June 2009.

<p>Temporal distribution of prevalence of <i>Plasmodium falciparum</i> malaria based on the U.N. populations at the UNMIS level 2 hospital in Wau, July 2006–June 2009.</p

Signs and symptoms among cases of <i>Plasmodium falciparum</i> malaria between the two groups.

#<p>Temperature under the arm >37.5°C.</p>*<p>Core body temperature >40°C.</p

Clinical features of esophageal cancer patients treated with elective nodal irradiation or involved-field irradiation.

<p>Clinical features of esophageal cancer patients treated with elective nodal irradiation or involved-field irradiation.</p

Overall survival (OS) and progression-free survival (PFS) curves illustrate the survival of all patients.

<p>For the whole cohort of patients with esophageal squamous cell cancer who underwent radiotherapy, the median OS and PFS were 16 months and 12 months, respectively. The 1-, 2-, and 3-year OS and PFS rates for the entire population were 62.8%, 35.0%, and 23.2%, and 47.4%, 29.1%, and 21.2%, respectively.</p

Progression-free survival (PFS) curves illustrate the survival of patients receiving elective nodal irradiation (ENI) and involved-field irradiation (IFI).

<p>The median PFS for patients in the IFI and ENI groups was 11 months and 13 months, respectively; the 1-, 2-, and 3-year PFS rates for patients between the IFI and ENI groups were 43.8%, 23.6%, and 21.0%, and 52.1%, 36.6% and 20.6%, respectively (<i>p</i> = 0.61).</p